- Home
- AVTX vs ABSI Comparison
AVTX vs ABSI Comparison
Compare AVTX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | ABSI |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.7M | 997.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AVTX | ABSI |
|---|---|---|
| Price | $18.82 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $40.57 | $6.96 |
| AVG Volume (30 Days) | 1.9M | ★ 7.7M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $6.21 | $2.24 |
| 52 Week High | $24.27 | $12.06 |
Technical Indicators
Market Signals| Indicator | AVTX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 42.90 |
| Support Level | $13.13 | $2.80 |
| Resistance Level | $19.06 | $12.06 |
| Average True Range (ATR) | 1.33 | 0.79 |
| MACD | -0.13 | -0.51 |
| Stochastic Oscillator | 48.39 | 15.38 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.